Profile data is unavailable for this security.
About the company
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
- Revenue in USD (TTM)37.19m
- Net income in USD-38.55m
- Incorporated2005
- Employees73.00
- LocationAssembly Biosciences IncTwo Tower Place, 7Th FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (212) 554-4388
- Fax+1 (646) 706-5101
- Websitehttps://www.assemblybio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | 246.72m | 64.45m | 432.31m | 82.00 | 9.19 | 0.8195 | 6.56 | 1.75 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 440.31m | 51.00 | -- | 1.64 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Verastem Inc | 13.38m | -241.11m | 441.33m | 78.00 | -- | -- | -- | 32.99 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 442.23m | 70.00 | -- | 20.06 | -- | 40.89 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 456.73m | 183.00 | -- | 1.34 | -- | 7.42 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 457.63m | 353.00 | -- | 2.83 | -- | 2.84 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 459.33m | 123.00 | -- | 36.62 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Prothena Corporation PLC | 9.68m | -244.09m | 466.71m | 163.00 | -- | 1.66 | -- | 48.19 | -4.53 | -4.53 | 0.1799 | 5.21 | 0.0222 | -- | -- | -- | -55.86 | -19.16 | -62.22 | -20.73 | -- | -- | -2,520.57 | -114.82 | -- | -- | -- | -- | -92.84 | 62.56 | -99.57 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 469.02m | 129.00 | -- | 2.37 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 471.98m | 73.00 | -- | 2.58 | -- | 12.69 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 483.82m | 100.00 | -- | 2.22 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Altimmune Inc | 20.00k | -83.92m | 486.31m | 59.00 | -- | 2.22 | -- | 24,315.64 | -1.07 | -1.07 | 0.0003 | 1.94 | 0.0001 | -- | 0.0314 | 338.98 | -45.82 | -42.36 | -48.64 | -45.46 | -- | -- | -419,575.00 | -3,193.88 | -- | -- | 0.0722 | -- | -95.31 | -67.83 | -7.48 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 487.52m | 17.00 | -- | 2.75 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 120.00k | -209.18m | 492.74m | 227.00 | -- | 1.22 | -- | 4,106.13 | -3.74 | -3.74 | 0.0022 | 7.89 | 0.0002 | -- | -- | 528.63 | -40.70 | -32.02 | -43.51 | -33.96 | -- | -- | -174,314.20 | -895.24 | -- | -- | 0.00 | -- | -99.82 | -64.94 | -59.53 | -- | 3.40 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 507.90m | 263.00 | -- | -- | -- | 6.75 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 509.85m | 300.00 | -- | 1.41 | -- | 12,435.49 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
Data as of Feb 27 2026. Currency figures normalised to Assembly Biosciences Inc's reporting currency: US Dollar USD
42.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Farallon Capital Management LLCas of 31 Dec 2025 | 1.23m | 7.89% |
| RA Capital Management LPas of 31 Dec 2025 | 1.02m | 6.56% |
| Commodore Capital LPas of 31 Dec 2025 | 1.00m | 6.43% |
| Janus Henderson Investors US LLCas of 31 Dec 2025 | 837.93k | 5.39% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2025 | 665.25k | 4.28% |
| Point72 Asset Management LPas of 31 Dec 2025 | 600.61k | 3.86% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 501.54k | 3.22% |
| Blackstone Alternative Asset Management LPas of 31 Dec 2025 | 318.75k | 2.05% |
| Parkman Healthcare Partners LLCas of 31 Dec 2025 | 249.36k | 1.60% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 210.53k | 1.35% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
